580 related articles for article (PubMed ID: 27702697)
1. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
Gonçalves VSS; Matias AA; Poejo J; Serra AT; Duarte CMM
Int J Pharm; 2016 Dec; 515(1-2):1-10. PubMed ID: 27702697
[TBL] [Abstract][Full Text] [Related]
2. Development and application of an ex vivo fosphenytoin nasal bioconversion/permeability evaluation method.
Antunes Viegas D; Rodrigues M; Francisco J; Falcão A; Alves G; Santos AO
Eur J Pharm Sci; 2016 Jun; 89():61-72. PubMed ID: 27106504
[TBL] [Abstract][Full Text] [Related]
3. Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies.
Gavini E; Rassu G; Sanna V; Cossu M; Giunchedi P
J Pharm Pharmacol; 2005 Mar; 57(3):287-94. PubMed ID: 15807983
[TBL] [Abstract][Full Text] [Related]
4. Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products.
Pozzoli M; Ong HX; Morgan L; Sukkar M; Traini D; Young PM; Sonvico F
Eur J Pharm Biopharm; 2016 Oct; 107():223-33. PubMed ID: 27418393
[TBL] [Abstract][Full Text] [Related]
5. Comparison of RPMI 2650 cell layers and excised sheep nasal epithelial tissues in terms of nasal drug delivery and immunocytochemistry properties.
Gerber W; Svitina H; Steyn D; Peterson B; Kotzé A; Weldon C; Hamman JH
J Pharmacol Toxicol Methods; 2022; 113():107131. PubMed ID: 34699972
[TBL] [Abstract][Full Text] [Related]
6. Supercritical fluid precipitation of ketoprofen in novel structured lipid carriers for enhanced mucosal delivery--a comparison with solid lipid particles.
Gonçalves VSS; Matias AA; Rodríguez-Rojo S; Nogueira ID; Duarte CMM
Int J Pharm; 2015 Nov; 495(1):302-311. PubMed ID: 26277371
[TBL] [Abstract][Full Text] [Related]
7. RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies.
Wengst A; Reichl S
Eur J Pharm Biopharm; 2010 Feb; 74(2):290-7. PubMed ID: 19733661
[TBL] [Abstract][Full Text] [Related]
8. Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting.
Gavini E; Rassu G; Ferraro L; Beggiato S; Alhalaweh A; Velaga S; Marchetti N; Bandiera P; Giunchedi P; Dalpiaz A
Eur J Pharm Biopharm; 2013 Feb; 83(2):174-83. PubMed ID: 23153670
[TBL] [Abstract][Full Text] [Related]
9. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
10. Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions.
Reichl S; Becker K
J Pharm Pharmacol; 2012 Nov; 64(11):1621-30. PubMed ID: 23058049
[TBL] [Abstract][Full Text] [Related]
11. Alginate-based hybrid aerogel microparticles for mucosal drug delivery.
Gonçalves VS; Gurikov P; Poejo J; Matias AA; Heinrich S; Duarte CM; Smirnova I
Eur J Pharm Biopharm; 2016 Oct; 107():160-70. PubMed ID: 27393563
[TBL] [Abstract][Full Text] [Related]
12. Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation.
Tas C; Ozkan CK; Savaser A; Ozkan Y; Tasdemir U; Altunay H
Drug Deliv; 2009 Apr; 16(3):167-75. PubMed ID: 19514977
[TBL] [Abstract][Full Text] [Related]
13. Lipid/alginate nanoparticle-loaded in situ gelling system tailored for dexamethasone nasal delivery.
Dukovski BJ; Plantić I; Čunčić I; Krtalić I; Juretić M; Pepić I; Lovrić J; Hafner A
Int J Pharm; 2017 Nov; 533(2):480-487. PubMed ID: 28577969
[TBL] [Abstract][Full Text] [Related]
14. Nasal administration of liquid crystal precursor mucoadhesive vehicle as an alternative antiretroviral therapy.
Carvalho FC; Campos ML; Peccinini RG; Gremião MP
Eur J Pharm Biopharm; 2013 May; 84(1):219-27. PubMed ID: 23207328
[TBL] [Abstract][Full Text] [Related]
15. Drug Permeation Characterization of Inhaled Dry Powder Formulations in Air-Liquid Interfaced Cell Layer Using an Improved, Simple Apparatus for Dispersion.
Asai A; Okuda T; Sonoda E; Yamauchi T; Kato S; Okamoto H
Pharm Res; 2016 Feb; 33(2):487-97. PubMed ID: 26490362
[TBL] [Abstract][Full Text] [Related]
16. Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles.
Trotta V; Pavan B; Ferraro L; Beggiato S; Traini D; Des Reis LG; Scalia S; Dalpiaz A
Eur J Pharm Biopharm; 2018 Jun; 127():250-259. PubMed ID: 29486302
[TBL] [Abstract][Full Text] [Related]
17. Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery.
Patil SB; Sawant KK
J Microencapsul; 2009 Aug; 26(5):432-43. PubMed ID: 18932060
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.
Ambrus R; Gieszinger P; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Janáky T; Tömösi F; Kecskeméti G; Szabó-Révész P; Bartos C
Molecules; 2020 Feb; 25(5):. PubMed ID: 32120992
[TBL] [Abstract][Full Text] [Related]
19. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery.
Alex AT; Joseph A; Shavi G; Rao JV; Udupa N
Drug Deliv; 2016 Sep; 23(7):2144-2153. PubMed ID: 25544603
[TBL] [Abstract][Full Text] [Related]
20. Assessment of cell viability and permeation enhancement in presence of lipid-based self-emulsifying drug delivery systems using Caco-2 cell model: Polysorbate 80 as the surfactant.
Bu P; Ji Y; Narayanan S; Dalrymple D; Cheng X; Serajuddin AT
Eur J Pharm Sci; 2017 Mar; 99():350-360. PubMed ID: 28024890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
